We are pleased to invite you to the Covance Clinical Oncology Symposium in Xiamen, China. Join our experts as they discuss biomarkers in immuno-oncology, companion diagnostics and diagnostic development in China.

TOPICS AND SPEAKERS

Welcome
Shukui Qin, MD, PhD
Chair of Chinese Society of Clinical Oncology (CSCO); Deputy Director of People's Liberation Army (PLA) 81 Hospital (Nanjing, China); Director of Cancer Center of Chinese PLA.

Prof. Dr. Shukui Qin is the deputy director of People's Liberation Army (PLA) 81 Hospital (Nanjing, China), director of Cancer Center of Chinese PLA, and director of National Drug Clinical Trial Agency of PLA 81 Hospital. He serves as the executive member of the Asian Clinical Oncology Society (ACOS), chair of Chinese Society of Clinical Oncology (CSCO), council member of PLA Medical Science Commission (and the executive member of its oncology society), Member of the oncology branch of Chinese Medical Association, expert committee member of national tumor standardized diagnosis and treatment of Ministry of Health (and also the leader of the Liver Cancer Expert Panel and Cancer Pain Expert Panel), vice president of Beijing Xisike Clinical Oncology Research Foundation, and member of Chinese Anti-cancer Association (CACA) (and the vice chairman of the Committee of Rehabilitation and Palliative Care affiliated to CACA).

The Role of Biomarkers in Immuno-Oncology Drug Development
Steven Anderson, PhD,
Senior Vice President and Chief Scientific Officer

Dr. Anderson provides scientific direction for new technologies and applications such as biomarker development, genomics and companion diagnostics. He also manages strategies for genomics, oncology and anatomic pathology, serving as a key global contact for clients and Covance scientific teams. Dr. Anderson brings over 25 years of experience to laboratory research and drug development.
TOPICS AND SPEAKERS (continued)

Insights and Approaches to Companion Diagnostics Development

Thomas Turi, PhD
Vice President Companion Diagnostics, Covance Laboratories

Dr. Turi joined Covance in 2008 to establish the biomarker center of excellence and currently develops and coordinates science and strategy for biomarkers, companion diagnostics and technology across Covance. He has more than 20 years of experience in drug discovery and development and leads operations for the newly launched companion diagnostics development laboratory.

An Update on Companion Diagnostics in Precision Oncology

Mike Zhu, MD, PhD
Executive Vice President, Amoy Diagnostics Co., LTD

Dr. Zhu is an executive leader of Amoy, which focuses on molecular diagnostics for personalized oncology treatments. His deep experience includes a leadership position at AstraZeneca to advance translational science and tumor genetics and he has also served as the chief scientific officer with a Chinese biotech company. Dr. Zhu worked as a physician of internal medicine in Shanghai for 11 years and has contributed to more than 40 peer reviewed and published articles.

We look forward to your attendance. Please RSVP to:
Shirley Zheng - Shirley.Zheng@covance.com

Learn more about our drug development solutions at www.covance.com

Covance Inc., headquartered in Princeton, NJ, USA is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.

The Americas 1.888.COVANCE (+1.888.268.2623) +1.609.452.4440
Europe / Africa +00.800.2682.2682 +44.1423.500888
Asia Pacific +800.6568.3000 +65.6.5686588

© Copyright 2017 Covance Inc.